Previous 10 | Next 10 |
2023-08-10 12:47:08 ET Liquidia Corporation (LQDA) Q2 2023 Earnings Conference Call August 10, 2023, 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty Schundler - General Counsel Mike Kaseta - Chi...
2023-08-10 06:11:53 ET Liquidia press release ( NASDAQ: LQDA ): Q2 GAAP EPS of -$0.36 misses by $0.19 . Revenue of $4.79M (+22.2% Y/Y) beats by $0.55M . Revenue related primarily to the promotion agreement between Liquidia PAH and Sandoz Inc, sharing profit der...
MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate ...
2023-08-09 14:14:08 ET Liquidia ( NASDAQ: LQDA ) is scheduled to announce Q2 earnings results on Thursday, August 10th, before market open. The consensus EPS Estimate is -$0.16 (-6.7% Y/Y) and the consensus Revenue Estimate is $4.24M (+8.7% Y/Y).Over the last 1 year, L...
MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a...
No new clinical data is required to add PH-ILD indication as per FDA correspondence Recertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for Tyvaso Preparing for potential launch of YUTREPIA between end of 2023 to mid-2024 MORRISVILLE, N.C., July...
Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR Federal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024 If PTAB decision affirmed, Liquidia will request final regulatory approval for YUTREPIA...
2023-06-29 13:06:21 ET Gainers: Immunome IMNM +31% . The Greenbrier Companies GBX +30% . Savers Value Village SVV +30% . Eco Wave Power Global ( WAVE ) +28% . Franklin Covey FC +26% . Trio Petroleum ( TPET ) +23% . Carriage Servi...
Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty Pharmosa to receive up to...
2023-06-23 13:40:23 ET Summary Liquidia and MannKind are competing to secure the most significant revenue stream for their respective PAH drugs, both containing the active ingredient Treprostinil. Liquidia's stock has increased by 96% in the past year, while MannKind's stock has r...
News, Short Squeeze, Breakout and More Instantly...
Liquidia Technologies Inc. Company Name:
LQDA Stock Symbol:
NASDAQ Market:
Liquidia Technologies Inc. Website:
2024-07-12 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues PERFORM recommendation for LQDA on June 24, 2024 04:14PM ET. LQDA was trading at $12.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recommendat...
Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liqui...